Analysis of US Marketed Artemisinin Supplements for Use in Dogs

• Published in: Journal of veterinary pharmacology and therapeutics 2024-08
• Main Authors: Berman, Alyssa R, Birkenheuer, Adam J, Sorah, Emily L, Papich, Mark G
• Format: Article
• Language: English
• ISSN: 0140-7783; 1365-2885; 1365-2885
• DOI: 10.1111/jvp.13480

Oral artemisinin has antiparasitic activity and may help improve treatment success rates in dogs infected with Babesia gibsoni. However, these artemisinin products are unapproved and unregulated botanical supplements. They have not been evaluated for safety and efficacy or for strength, purity, or quality compared with a reference standard. Before considering these products for a clinical study, we evaluated the strength of four suppliers of artemisinin capsules using an high-performance liquid chromatography method validated in our laboratory. We found that the four artemisinin-labeled products that were tested had high within product and between product variability in capsule strength compared with the stated capsule strength on the product label. No products met the acceptance criteria of the United States Pharmacopeia and International Council for Harmonisation (ICH) as well as the criteria adapted by the authors. One product had no detectable artemisinin, and the other three products were much higher than the stated label strength. The results of this study reinforce the importance of testing unapproved and unregulated supplements before recommending a supplement for clinical use in dogs.